Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
38376
CAS Number:
72559-06-9
Rifabutina
Grade:
cumple con la especificación USP
Purity:
950 - 1020 ìg/mg (ensayo)
Synonym(s):
Ansamicina, LM-427
Documents
$35.00 /100 mg
Tamaño
ìg/mg (ensayo)">
Request Bulk Quote
Información del producto

Rifabutin is a potent antibiotic belonging to the ansamycin class, primarily used in the treatment of tuberculosis and other mycobacterial infections. Its unique mechanism of action involves inhibiting bacterial RNA synthesis, making it effective against resistant strains of Mycobacterium tuberculosis. This compound is particularly beneficial for patients with HIV co-infection, as it can be used as a prophylactic treatment to prevent the onset of disseminated Mycobacterium avium complex (MAC) disease.

In addition to its therapeutic applications, Rifabutin is also utilized in research settings to study antibiotic resistance and the efficacy of combination therapies. Its favorable pharmacokinetic properties, including a long half-life and good oral bioavailability, make it a preferred choice for clinicians aiming to optimize treatment regimens. Researchers and healthcare professionals appreciate Rifabutin for its ability to maintain effectiveness in challenging cases, providing a reliable option in the fight against resistant infections.

Número CAS
72559-06-9
Fórmula molecular
C46H62N4O11
Peso molecular
847.02
Número MDL
MFCD00866816
Condiciones
Conservar entre 0 y 8 °C.
Información general
Número CAS
72559-06-9
Fórmula molecular
C46H62N4O11
Peso molecular
847.02
Número MDL
MFCD00866816
Condiciones
Conservar entre 0 y 8 °C.
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Rifabutin is widely utilized in research focused on

  • Treatment of Tuberculosis: Primarily used as an antibiotic to treat tuberculosis, especially in patients with HIV, enhancing patient outcomes and reducing the risk of drug resistance.
  • HIV Co-infection Management: Effective in managing opportunistic infections in HIV-positive patients, providing a critical option for healthcare providers in improving overall patient health.
  • Pharmaceutical Research: Employed in the development of new formulations and delivery methods, aiding researchers in creating more effective treatments with fewer side effects.
  • Clinical Trials: Frequently used in clinical studies to evaluate its efficacy and safety, contributing to the advancement of medical knowledge and treatment protocols.
  • Public Health Initiatives: Plays a role in global health programs aimed at controlling tuberculosis, particularly in high-burden countries, supporting efforts to reduce disease prevalence.

Citas